Background/Aims: The aims of this study were to validate the newly developed version of the Addenbrooke's Cognitive Examination (ACE-III) against standardised neuropsychological tests and its predecessor (ACE-R) in early dementia. Methods: A total of 61 patients with dementia (frontotemporal dementia, FTD, n = 33, and Alzheimer's disease, AD, n = 28) and 25 controls were included in the study. Results: ACE-III cognitive domains correlated significantly with standardised neuropsychological tests used in the assessment of attention, language, verbal memory and visuospatial function. The ACE-III also compared very favourably with its predecessor, the ACE-R, with similar levels of sensitivity and specificity. Conclusion: The results of this study provide objective validation of the ACE-III as a screening tool for cognitive deficits in FTD and AD.

Keywords:
Alzheimer’s disease, Cognitive screening test, Frontotemporal dementia, Neuropsychological tests
1.
Mioshi E, Dawson K, Mitchell J, et al: The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. In J Geriatr Psychiatry 2006;21:1078-1085.
2.
Hsieh S, Hodges JR, Leyton CE, Mioshi E: Longitudinal changes in the primary progressive aphasias: differences in cognitive and dementia staging measures. Dement Geriatr Cogn Disord 2012;34:135-141.
3.
Raimondi C, Gleichgerrcht E, Richly P, et al: The Spanish version of the Addenbrooke's Cognitive Examination - Revised (ACE-R) in subcortical ischemic vascular dementia. J Neurol Sci 2012;322:228-231.
4.
Mathew R, Bak TH, Hodges JR: Screening for cognitive dysfunction in corticobasal syndrome: utility of Addenbrooke's cognitive examination. Dement Geriatr Cogn Disord 2011;31:254-258.
5.
Kipps CM, et al: Measuring progression in frontotemporal dementia: implications for therapeutic interventions. Neurology 2008;70:2046-2052.
6.
Alexopoulos P, et al: Validation of the German revised Addenbrooke's cognitive examination for detecting mild cognitive impairment, mild dementia in Alzheimer's disease and frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2010;29:448-456.
7.
Dos Santos Kawata KH, Hashimoto R, Nishio Y, et al: A Validation Study of the Japanese Version of the Addenbrooke's Cognitive Examination-Revised. Dement Geriatr Cogn Disord Extra 2012;2:29-37.
8.
Carvalho VA, Barbosa MT, Caramelli P: Brazilian version of the Addenbrooke Cognitive Examination-revised in the diagnosis of mild Alzheimer disease. Cogn Behav Neurol 2010;23:8-13.
9.
Chen ST, Sultzer DL, Hinkin CH, et al: Executive dysfunction in Alzheimer's disease: association with neuropsychiatric symptoms and functional impairment. J Neuropsychiatry Clin Neurosci 1998;10:426-432.
10.
Crawford S, et al: A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination-Revised in the diagnosis of dementia. Int J Geriatr Psychiatry 2012;27:659-669.
11.
Davies RR, Larner AJ: Addenbrooke's Cognitive Examination (ACE) and Its Revision (ACE-R), in Cognitive Screening Instruments. London, Springer, 2013, pp 61-77.
12.
Valcour VG, Masaki KH, Blanchette PL: The phrase: ‘no ifs, ands, or buts' and cognitive testing. Lessons from an Asian-American community. Hawaii Med J 2002;61:72-74.
13.
Werner P, et al: ‘Yes' ifs, ands or buts: examining performance and correlates of the repetition task in the Mini-Mental State Examination. Int J Geriatr Psychiatry 1999;14:719-725.
14.
Brugnolo A, Nobili F, Barbieri MP, et al: The factorial structure of the Mini Mental State Examination (MMSE) in Alzheimer's disease. Arch Gerontol Geriatr 2009;49:180-185.
15.
Ganguli M, Ratcliff G, Huff FJ, et al: Serial sevens versus world backwards: a comparison of the two measures of attention from the MMSE. J Geriatr Psychiatry Neurol 1990;3:203-207.
16.
Rascovsky K, et al: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
17.
Gorno-Tempini ML, et al: Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-1014.
18.
McKhann GM, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
19.
Mioshi E, et al: Clinical staging and disease progression in frontotemporal dementia. Neurology 2010;74:1591-1597.
20.
Benton AL, Hamsher KD, Sivan AB: Multilingual Aphasia Examination, ed 3. San Antonio, Psychological Corporation, 1994.
21.
Wechsler D: Wechsler Adult Intelligence Scale, ed 3. San Antonio, Psychological Corporation, 1997.
22.
Strauss E, Sherman EMS, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, ed 3. Oxford, Oxford University Press, 2006.
23.
Savage S, Hsieh S, Leslie F, et al: Distinguishing subtypes in primary progressive aphasia: application of the Sydney Language Battery. Dement Geriatr Cogn Disord 2013;35:208-218.
24.
Perri R, et al: Alzheimer's disease and frontal variant of frontotemporal dementia - a very brief battery for cognitive and behavioural distinction. J Neurol 2005;252:1238-1244.
25.
Libon DJ, et al: Screening for frontotemporal dementias and Alzheimer's disease with the Philadelphia Brief Assessment of Cognition: a preliminary analysis. Dement Geriatr Cogn Disord 2007;24:441-447.
26.
Harciarek M, Jodzio K: Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review. Neuropsychol Rev 2005;15:131-145.
27.
Hodges JR, et al: The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimer's disease: a comparative neuropsychological study. Neuropsychology 1999;13:31-40.
28.
Hornberger M, Piguet O, Graham AJ, et al: How preserved is episodic memory in behavioral variant frontotemporal dementia? Neurology 2010;74:472-479.
29.
Piguet O, et al: Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011;10:162-172.
30.
Wear HJ, et al: The Cambridge Behavioural Inventory revised. Dement Neuropsychol 2008;2:102-107.
31.
Cummings JL, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
32.
Leyton CE, et al: Application of Addenbrooke's cognitive examination to diagnosis and monitoring of progressive primary aphasia. Dement Geriatr Cogn Disord 2010;29:504-509.
33.
Jang J, et al: Activities of daily living in progressive non-fluent aphasia, logopenic progressive aphasia and Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:354-360.
34.
Yew B, et al: Lost and forgotten? Orientation versus memory in Alzheimer's disease and frontotemporal dementia. J Alzheimers Dis 2013;33:473-481.
35.
Rowland JT, Basic D, Storey JE, Conforti DA.: The Rowland Universal Dementia Assessment Scale (RUDAS) and the Folstein MMSE in a multicultural cohort of elderly persons. Int Psychogeriatr 2006;18:111-120.
36.
Nasreddine ZS, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.